Stay updated on INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Sign up to get notified when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The website has been updated from version v2.14.1 to v2.14.2.
    Difference
    0.0%
    Check dated 2025-02-03T07:43:39.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    The website has been updated from version 2.14.0 to 2.14.1.
    Difference
    0.0%
    Check dated 2025-01-19T22:12:37.000Z thumbnail image
  4. Check
    24 days ago
    Change Detected
    Summary
    The website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.
    Difference
    0.1%
    Check dated 2025-01-12T17:42:18.000Z thumbnail image
  5. Check
    52 days ago
    Change Detected
    Summary
    The website has been updated to version v2.13.3 with new additions from December 2024, while the previous version v2.13.2 and several September 2024 entries have been removed.
    Difference
    0.2%
    Check dated 2024-12-14T22:37:19.000Z thumbnail image
  6. Check
    60 days ago
    Change Detected
    Summary
    The website has updated the contact details section for the study, clarifying that it now provides information for individuals who can answer questions about joining the study, along with the study's location.
    Difference
    0.7%
    Check dated 2024-12-07T16:00:16.000Z thumbnail image
  7. Check
    74 days ago
    Change Detected
    Summary
    The website has added new features for user interaction, while several detailed data fields and options for downloading study information have been removed.
    Difference
    1%
    Check dated 2024-11-23T04:32:50.000Z thumbnail image

Stay in the know with updates to INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the INSIGHT 2: Tepotinib+Osimertinib in MET+ NSCLC Clinical Trial page.